Optivia, A BioIVT Company

Validated DDI transporter assays with submission quality reports and agency approved substrates and inhibitors.

Optivia’s Opti-DDI™ Transporter Services Panel provides you with FDA, EMA & PMDA compliant services to help you meet your regulatory requirements. We provide unprecedented transporter assay capability and expertise in transporter DDIs and FDA/EMA/PMDA compliant transporter studies. Our award-winning transporter DDI services include robust validated assays with agency approved substrates and inhibitors, expert advice on study design, and regulatory submission quality reports, as well as guidance on additional transporters the agencies often request.

For more information, please visit www.optiviabio.com/ddi-transporters/

As the industry's leading drug transporter research solution provider, Optivia offers more than 80 transporter assay services and specialized transporter panels to help you select drug candidates with desirable transporter-interaction profiles, elucidate MOA of off-target clinical responses, and enhance the commercial potential of your drugs through identifying potential new therapeutic indications.

• Opti-DDI™ Panel: Select and optimize preclinical candidates with less DDI liability (www.optiviabio.com/ddi-transporters/)

• Opti-Target™ Panel: Profile of therapeutic transporter targets for studying the MOA of off-target clinical outcomes and for identifying new therapeutic indications for approved or experimental drugs (www.optiviabio.com/transporter-target-panel/)

• Opti-Safety ™ Panel: Identify safety liabilities of preclinical candidates by avoiding undesirable interactions with toxicity related transporters (www.optiviabio.com/safety-transporters/)

• Opti-ADME™ Panel: Elucidate key ADME pathways and determinants for predicting the pharmacological attributes of preclinical candidate and tissue targeting (www.optiviabio.com/adme-transporters/)

Key Features of Optivia's assay services:

• Turn-key solution with fast turnaround time
  
• Both inhibitor and substrate tests are provided
  
• Available for a large panel of clinically-relevant DDI, ADME, Toxicity and therapeutic target transporters
  
• Reliable and biologically relevant data from robust functional assays designed to meet stringent regulatory standards
  
• All assay models overexpress recombinant transporters, providing clean and definitive results
  
• Free technical consultation from experienced, customer-oriented scientists
  

For a complete list of our transporter assays, please visit www.optiviabio.com/transporter-assays-a-z/

Optivia provides definitive functional substrate and inhibition assays for the following monoamine transporters:

SERT: Serotonin transporter (SLC6A4)
NET: Norepinephrine transporter (SLC6A2)
DAT: Dopamine transporter (SLC6A3)
PMAT: Plasma membrane monoamine transporter (ENT4, SLC29A4)
OCT3: Organic cation transporter 3 (SLC22A3)

Typical turnaround time: 2-4 weeks
Types of studies: IND/NDA enabling, discovery screening, mechanistic profiling

Optivia provides definitive functional substrate and inhibition assays for the following major nucleoside transporters:

CNT1 (human and rat): Concentrative nucleoside transporter 1 (SLC28A1)
CNT2 (human and rat): Concentrative nucleoside transporter 1 (SLC28A2)
CNT3 (human and rat): Concentrative nucleoside transporter 1 (SLC28A3)
ENT1: Equilibrative nucleoside transporter 1 (SLC29A1)
ENT2: Equilibrative nucleoside transporter 1 (SLC29A2)
ENT4: Equilibrative nucleoside transporter 1 (SLC29A4)

Typical turnaround time: 2-4 weeks
Types of studies: IND/NDA enabling, discovery screening and mechanistic profiling

As the industry's leading transporter research solution provider, Optivia provides definitive, validated functional assays for a variety of amino acid transporters:

Asc-1: Alanine, serine, cysteine transporter 1 (SLC7A10)
ASCT2: Alanine, serine, cysteine transporter 2 (SLC1A5)
ATB0+: Sodium- and chloride-dependent neutral and basic amino acid transporter B (0+) (SLC6A14)
CAT3: Cationic amino acid transporter 3 (SLC7A3)
EAAT1 (GLAST-1): Excitatory amino acid transporter 1 (SLC1A3)
EAAT2 (GLT-1): Excitatory amino acid transporter 2 (SLC1A2)
EAAT3 (EAAC1): Excitatory amino acid transporter 3 (SLC1A1)
GAT1: y-aminobutyric acid (GABA) transporter 1 (SLC6A1)
GAT2: y-aminobutyric acid (GABA) transporter 2 (SLC6A13)
GAT3: y-aminobutyric acid (GABA) transporter 1 (SLC6A11)
GLYT1: Glycine transporter 1 (SLC6A9)
LAT1: L-type amino acid transporter 1 (SLC7A5)
SNAT1: Sodium-coupled neutral amino acid transporter1 (SLC38A1)
SNAT2: Sodium-coupled neutral amino acid transporter1 (SLC38A2)
xCT: cystine/glutamate exchanger (SLC7A11)

Typical turnaround time: 2-4 weeks
Types of studies: IND/NDA enabling, discovery screening, mechanistic profiling

The following functional amino acid transporters can be validated within 2-3 weeks upon request:
CAT1: Cationic amino acid transporter 1 (SLC7A1)
CAT2: Cationic amino acid transporter 1 (SLC7A2)
CHT: Choline transporter (SLC5A7)
GLYT2: Glycine transporter 2 (SLC6A5).
SBAT1: Sodium-dependent neutral amino acid transporter B(0)AT2 (SLC6A15)

For other amino acid transporters not on the lists above, please inquire on our expedited assay development service, which typically takes 4-6 weeks to have a new transporter assay fully characterized and validated.

Typical turnaround time: 1-2 weeks
Minimal number of compounds per batch: 2

As the industry's leading drug transporter research solution provider, Optivia offers more than 80 transporter assay services and specialized transporter panels to help you select drug candidates with desirable transporter-interaction profiles, elucidate MOA of off-target clinical responses, and enhance the commercial potential of your drugs through identifying potential new therapeutic indications.

• Opti-DDI™ Panel: Select and optimize preclinical candidates with less DDI liability
  
• Opti-Target™ Panel: Profile of therapeutic transporter targets for studying the MOA of off-target clinical outcomes and for identifying new therapeutic indications for approved or experimental drugs
  
• Opti-Safety ™ Panel: Identify safety liabilities of preclinical candidates by avoiding undesirable interactions with toxicity related transporters
  
• Opti-ADME™ Panel: Elucidate key ADME pathways and determinants for predicting the pharmacological attributes of preclinical candidatesd tissue targeting
  

Key Features of Optivia's assay services:

• Turn-key solution with fast turnaround time
  
• Both inhibitor and substrate tests are provided
  
• Available for a large panel of clinically-relevant DDI, ADME, Toxicity and therapeutic target transporters
  
• Reliable and biologically relevant data from robust functional assays designed to meet stringent regulatory standards
  
• All assay models overexpress recombinant transporters, providing clean and definitive results
  
• Free technical consultation from experienced, customer-oriented scientists
  

As the industry's leading drug transporter research solution provider, Optivia offers more than 80 transporter assay services and specialized transporter panels to help you select drug candidates with desirable transporter-interaction profiles, elucidate MOA of off-target clinical responses, and enhance the commercial potential of your drugs through identifying potential new therapeutic indications.

Opti-DDI™ Panel: Select and optimize preclinical candidates with less DDI liability
Opti-Target™ Panel: Profile of therapeutic transporter targets for studying the MOA of off-target clinical outcomes and for identifying new therapeutic indications for approved or experimental drugs
Opti-Safety ™ Panel: Identify safety liabilities of preclinical candidates by avoiding undesirable interactions with toxicity related transporters
Opti-ADME™ Panel: Elucidate key ADME pathways and determinants for predicting the pharmacological attributes of preclinical candidatesd tissue targeting
Key Features of Optivia's assay services:

Turn-key solution with fast turnaround time
Both inhibitor and substrate tests are provided
Available for a large panel of clinically-relevant DDI, ADME, Toxicity and therapeutic target transporters
Reliable and biologically relevant data from robust functional assays designed to meet stringent regulatory standards
All assay models overexpress recombinant transporters, providing clean and definitive results
Free technical consultation from experienced, customer-oriented scientists